Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Kedrion-Growth-10pc

More Like This

Calliditas Therapeutics provides business update ahead of JP Morgan conference

Prothena Announces Corporate Restructuring

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

LifeArc Ventures 2024: new investments, targeted follow-ons and substantive portfolio progress

Immunovia Publishes Full Year Report for 2023

Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results

Allogeneic Cell Therapy to Treat Corneal Endothelial Disease (Graphic: Business Wire)

Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea

Almirall HQ in Barcelona (Photo: Business Wire)

Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline